Skip to main content

Table 3 Impact of infiltration by various immune cell subtypes on disease-free survival (DFS)

From: Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

  Cut-off value* DFS p
Immune cells in primary tumor
CD3 >3.04 (n = 16) vs. ≤ 3.04 (n = 16) 85% vs. 67% 0.4
CD8 >2.49(n = 16) vs. ≤ 2.49(n = 16) 79% vs. 69% 0.29
FoxP3 >1.81 (n = 17) vs. ≤ 1.81(n = 15) 86% vs. 63% 0.27
CD20 >0.23 (n = 18) vs. ≤ 0.23(n = 13) 83% vs. 81% 0.8
CD68 >1.02 (n = 16) vs. ≤ 1.02(n = 16) 73% vs. 75% 0.8
Granzyme B >0 (n = 18) vs. = 0(n = 15) 82% vs. 68% 0.53
Intraepithelial immune cells in metastatic lymph nodes
CD3 >3.52 (n = 13) vs. ≤ 3.52 (n = 14) 77% vs. 62% 0.26
CD8 >1.29 (n = 14) vs. ≤ 1.29 (n = 14) 91% vs. 53% 0.07
FoxP3 >2.26 (n = 14) vs. ≤ 2.26 (n = 13) 84% vs. 53% 0.17
CD20 >1.76 (n = 12) vs. ≤ 1.76 (n = 11) 82% vs. 60% 0.29
CD68 >1.05 (n = 14) vs. ≤ 1.05 (n = 13) 67% vs.73% 0.9
Granzyme B >0 (n = 11) vs. = 0(n = 19) 80% vs. 68% 0.46
Peritumoral immune cells in lymphatic tissue of metastatic nodes
CD3 >204.5 (n = 13) vs. ≤ 204.5 (n = 13) 66.7% vs. 80.8% 0.25
CD8 > 37.5 (n = 12) vs. ≤ 37.5 (n = 12) 72.7% vs. 76.4% 0.53
FoxP3 > 44 (n = 11) vs. ≤ 44 (n = 12) 90.9% vs. 62.3% 0.18
CD20 > 192 (n = 11) vs. ≤ 192 (n = 11) 100% vs. 63.6% 0.039
CD68 > 5.5 (n = 13) vs. ≤ 5.5 (n = 13) 76.9% vs. 81.5% 0.5
Granzyme B >0 (n = 15) vs. = 0 (n = 15) 78.6% vs.67.3% 0.65
Immune cells in uninvolved regional lymph nodes
CD3 >183 (n = 15) vs. ≤ 183 (n = 16) 75.0% vs. 73.3% 0.675
CD8 >88 (n = 15) vs. ≤ 88 (n = 16) 84.6% vs. 65.6% 0.337
FoxP3 >49 (n = 15) vs. ≤ 49 (n = 16) 78.6% vs. 71.1% 0.905
CD20 >147 (n = 15) vs. ≤ 147 (n = 16) 79% vs. 68.6% 0.779
CD68 >4 (n = 12) vs. ≤ 4 (n = 17) 75.8% vs. 68.8% 0.424
Granzyme B >0 (n = 13) vs. = 0 (n = 15) 73.3% vs.68.8% 0.939
  1. *Median was used as cut-off